Sprout Health Review 2026: Tirzepatide, Cost, and Fine Print

Quick answer: Is Sprout Health legitimate?

Sprout Health appears to be an identifiable telehealth administration platform that connects users with independent licensed clinicians and third-party pharmacies. Its public pages describe prescription review, follow-up access, monthly refill forms, portal messaging, and home delivery when treatment is prescribed.

The main consumer caution is not whether the company exists. It is whether the exact medication, pharmacy, total recurring price, refund cutoff, and state availability are clear before payment. Sprout publishes useful information, but its marketing pages and formal policy do not always describe refund timing in the same way.

Sprout also received an FDA warning letter dated September 9, 2025. FDA said a website claim falsely or misleadingly implied that Sprout’s compounded semaglutide and tirzepatide products were FDA-approved. Current Sprout pages now state that compounded products are not FDA-approved. A current FDA-site search on August 8, 2026 did not surface a close-out letter.

Our assessment: Sprout Health is a legitimate provider to research and compare, but consumers should verify the exact product, dispensing pharmacy, recurring charge, refund deadline, and state eligibility in writing before paying.

Review Sprout Health’s Current Program and Terms

Affiliate disclosure: Care Path Compare may receive compensation if you use a Sprout Health link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.

Does Sprout Health offer compounded tirzepatide?

Yes. Sprout Health currently advertises compounded tirzepatide, including a dedicated injection pathway. Broader Sprout GLP-1 materials also mention tirzepatide in tablet or injection form. A licensed clinician decides whether treatment is appropriate and what, if anything, to prescribe.

The pricing needs qualification. Sprout’s homepage currently shows compounded tirzepatide starting at $199 per month. Its dedicated tirzepatide page says starting at $349 and now from $199. But the main GLP-1 FAQ still states $349 per month for compounded tirzepatide and advertises $50 off the first month. These are different public funnels, so $199 should be treated as a starting or promotional price, not a guaranteed ongoing rate.

Compounded tirzepatide is not FDA-approved and should not be described as generic Zepbound or as equivalent or interchangeable with an FDA-approved product. Confirm the formulation, price, renewal amount, dispensing pharmacy, and state availability before paying.

Sprout Health at a glance

Information was checked August 8, 2026 and can change.

How Sprout Health says the program works

Sprout describes a mostly online sequence:

1. Complete a short prequalification quiz.
2. Purchase the recommended plan if the initial answers meet the funnel criteria.
3. Complete a more detailed medical questionnaire.
4. Have an independent licensed clinician review the information.
5. Receive a prescription only if the clinician considers treatment appropriate.
6. Have the prescription sent to a partner pharmacy for fulfillment.
7. Use the customer and medical portals for shipment tracking, refill forms, questions, and follow-up support.

The initial quiz is not a medical approval. The provider reviewing the detailed intake decides whether to prescribe, what to prescribe, and what dose or follow-up is appropriate.

Sprout’s main program page says delivery is typically three to five business days after a prescription is approved and processed. Another section describes five to seven business days from prescribing to delivery. Treat these as estimates rather than guarantees.

What medications does Sprout Health advertise?

Compounded semaglutide

Sprout advertises compounded semaglutide injections and, on some funnels, other compounded presentations. Compounded semaglutide is not FDA-approved. FDA does not evaluate a compounded product before marketing for safety, effectiveness, or quality in the same way it evaluates an approved drug.

Consumers should ask for the exact active ingredient, concentration, dosage form, dispensing pharmacy, storage instructions, beyond-use date, and prescribing rationale before shipment.

Compounded tirzepatide

Sprout currently advertises compounded tirzepatide. Its dedicated tirzepatide page is injection-specific, while broader GLP-1 funnels also reference tirzepatide in tablet or injection form. A licensed clinician determines whether a prescription is appropriate and which formulation, if any, to prescribe.

The public price presentation is not uniform. Sprout’s homepage currently shows compounded tirzepatide starting at $199 per month. The dedicated tirzepatide page says starting at $349 and now from $199, while the main GLP-1 FAQ lists $349 per month and a $50 first-month discount. Treat $199 as a starting or promotional figure rather than a verified universal recurring price.

These compounded products are not FDA-approved and should not be described as generic Zepbound or as equivalent or interchangeable with an FDA-approved product. Evidence from an approved injectable product should not automatically be applied to a different compounded formulation or route of administration.

Branded medication references

Some Sprout pages discuss Wegovy and Zepbound, but the clearest public program pricing we found was for compounded semaglutide and tirzepatide. Consumers seeking a branded product should confirm whether Sprout currently offers that pathway in their state, whether the medication cost is included, and whether insurance support is available.

How much does Sprout Health cost?

Sprout’s main GLP-1 program page displayed the following standard monthly prices on August 8, 2026:

The same page advertised $50 off the first month. At the same time, Sprout’s homepage displayed compounded semaglutide from $149 per month and compounded tirzepatide from $199 per month, while the dedicated tirzepatide page displayed “Starting at $349” and “Now from $199.” Separate promotional funnels also show first-month and multi-month discounts.

These starting and promotional figures should not be treated as universal recurring prices. The $349 tirzepatide figure remains the standard monthly amount stated in Sprout’s main GLP-1 FAQ, so consumers should verify which price, formulation, and renewal terms apply to the checkout they actually see. Before paying, confirm:

• the amount charged today;
• whether the plan is monthly or prepaid;
• the standard renewal amount;
• whether medication, shipping, clinician review, and follow-up remain included;
• whether the price stays fixed when dosage changes;
• the date of the next automatic charge; and
• the exact cancellation and refund terms attached to that checkout.

Sprout says the agreed monthly medication price is honored when dosage increases, excluding introductory discounts. Save a copy of that statement and the final checkout terms because promotional pages can change.

See our online GLP-1 program cost guide for a worksheet that separates introductory pricing from ongoing costs.

What does the membership include?

Sprout’s public pages describe a bundled compounded program that may include:

• clinician review and a prescription when medically appropriate;
• follow-up appointments;
• portal messaging with the licensed clinician;
• a four-week medication supply when prescribed;
• refill review forms;
• shipping; and
• customer support.

The pages reviewed did not clearly explain whether laboratory testing is required, when it may be ordered, who orders it, or whether laboratory costs are included. Ask about this before enrollment, especially if your medical history may require testing or closer monitoring.

Clinician access and refills

Sprout says users receive access to a medical portal after enrollment. The public refill instructions say a patient can complete a refill intake after the third dose of the current month. A clinician reviews that refill form before issuing the next prescription.

Users can also book an appointment through the portal to discuss side effects or treatment questions. That is more than an initial intake-only model, although the exact response time and appointment availability are not clearly guaranteed on the public pages we reviewed.

Pharmacy transparency

Sprout’s HIPAA notice names MD Integrations, Foothills Pharmacy, and Promise Pharmacy as external contacts. This is a useful transparency signal because it identifies entities involved in care administration or pharmacy services.

It does not establish that Foothills or Promise fills every prescription. Before fulfillment, ask for the legal name and location of the pharmacy assigned to your order and verify its license with the applicable state board of pharmacy.

Also confirm the exact formulation, concentration, storage conditions, delivery temperature guidance, damaged-shipment process, and contact for medication questions.

Cancellation and refund policy

Sprout’s public materials contain materially different refund descriptions.

The main GLP-1 page says a full refund is available before medication is processed by the partner pharmacy and says refunds are unavailable after a prescription is processed and sent to the pharmacy. A promotional page says a full refund is available before the prescription is written by the doctor.

Sprout’s current formal Refund and Returns Policy is more restrictive than some marketing summaries. It states that prescription medications cannot be returned and that all prescription medications are non-refundable. It separately asks customers to report damaged, lost, or unreceived medication within 48 hours so Sprout can assess a possible replacement-order credit.

Meanwhile, the main GLP-1 FAQ says a full refund is available before medication is processed by the partner pharmacy and that refunds are unavailable once a prescription is processed and sent to the pharmacy. Other promotional pages use an earlier cutoff, such as before the prescription is written.

Because these public descriptions are not fully synchronized, consumers should save the exact checkout terms and request written confirmation before relying on a refund promise. Canceling a future subscription and obtaining a refund for an existing prescription charge are separate issues.

Use our cancellation and refund guide before enrolling in any recurring telehealth program.

FDA warning-letter context

FDA issued Sprout Health Partners LLC a warning letter dated September 9, 2025. FDA said Sprout’s website used the statement that “GLP-1 medications are FDA-approved and backed by extensive clinical research” in a way that implied its compounded semaglutide and tirzepatide products were the same as FDA-approved products.

FDA stated that compounded drug products are not FDA-approved and characterized the claim as false or misleading. The letter instructed Sprout to address the cited violation and explain corrective steps.

Current Sprout pages reviewed on August 2, 2026 contain clearer disclosures that compounded GLP-1 products are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality. That is an improvement in current public wording. We did not locate an FDA close-out letter or other public FDA statement confirming formal resolution.

This context does not by itself establish the quality of an individual prescription or pharmacy shipment. It does make accurate product identification and careful review of marketing claims especially important.

Main strengths

• Standard monthly prices for the principal compounded injection programs are publicly displayed.
• Medication, clinician review, follow-up, messaging, and shipping are presented as included.
• The program describes a recurring refill-review process and access to clinicians after enrollment.
• The HIPAA notice names medical-service and pharmacy contacts.
• Current pages clearly state that compounded products are not FDA-approved.

Main limitations and questions to verify

• Promotional pricing varies by landing page and may obscure the recurring amount.
• Refund cutoff language differs across marketing pages and the formal policy.
• The dedicated tirzepatide page names Arkansas, Kansas, and New Mexico as partner-pharmacy shipping exceptions for that pathway; availability should still be reconfirmed during intake for the exact product and formulation.
• The actual dispensing pharmacy is not guaranteed before assignment.
• Laboratory requirements and costs are not clearly disclosed.
• FDA issued a 2025 warning letter about misleading FDA-approval language; a current FDA-site search on August 8, 2026 did not surface a close-out letter.
• Some marketing pages use aggressive outcome language that should not be treated as a guaranteed or typical result.

Who may find Sprout Health worth comparing?

Sprout may be worth comparing for adults who want a bundled cash-pay telehealth program with publicly displayed standard pricing, medication shipping, refill review, and ongoing portal access.

It may be less suitable for someone who needs insurance billing, wants a named dispensing pharmacy before purchase, needs a clearly documented laboratory policy, or is uncomfortable with inconsistencies between promotional and formal refund language.

Questions to ask before paying

1. What exact medication, formulation, route, and concentration would be prescribed if I am eligible?
2. Which licensed pharmacy would dispense my prescription?
3. What is today’s charge, and what is the standard recurring charge after the promotion?
4. Is this monthly, prepaid, or a multi-month commitment?
5. What is the exact deadline to cancel before the next charge?
6. Which refund rule controls if the clinician has reviewed my intake but the pharmacy has not received the prescription?
7. Are laboratory tests required, and who pays for them?
8. Is the program currently available in my state for the specific medication and dosage form?
9. How do I contact the clinician between refill reviews?
10. What happens if a shipment is delayed, warm, damaged, or missing?

Bottom line

Sprout Health provides enough public information to merit inclusion in a telehealth comparison. Its main GLP-1 FAQ still publishes standard monthly prices, while its homepage and tirzepatide page now layer lower starting or promotional figures on top of those standard amounts. Its public model includes clinician review, follow-up access, medication when prescribed, and shipping.

The most important unresolved consumer issues are the difference between the $199 tirzepatide starting presentation and the $349 standard monthly figure, inconsistent refund descriptions, product-specific state availability, undisclosed laboratory policy, and the need to identify the actual dispensing pharmacy. The 2025 FDA warning letter also makes careful distinction between compounded and FDA-approved products essential.

Review the final checkout terms rather than relying on a landing-page headline, and talk with the assigned licensed provider about eligibility, risks, alternatives, and monitoring.

Check Sprout Health’s Current Pricing and Checkout Details

·

Review our provider-verification checklist

Affiliate disclosure: Care Path Compare may receive compensation if you use a Sprout Health link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions.